Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Type 1: A Light on Molecular Mechanisms
Author(s) -
Koen L. A. Vanderschuren,
Tom Sieverink,
Ronald Wilders
Publication year - 2013
Publication title -
genetics research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 9
eISSN - 2090-3154
pISSN - 2090-3162
DOI - 10.1155/2013/460805
Subject(s) - arrhythmogenic right ventricular dysplasia , cardiomyopathy , medicine , ventricle , dysplasia , smad , transforming growth factor , cardiology , heart failure
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy associated with cardiac arrhythmias originating in the right ventricle, heart failure, and sudden cardiac death. Development of ARVD/C type 1 has been attributed to differential expression of transforming growth factor beta 3 (TGF β 3). Several mechanisms underlying the molecular basis of ARVD/C type 1 have been proposed. Evaluating previously described mechanisms might elucidate how TGF β 3 contributes to disease progression in ARVD/C type 1. Here we review how TGF β 3 can induce fibrogenesis through Smad and/or β -catenin signaling. Moreover, the role of apoptosis is addressed. Finally the extent to which the immune system has been demonstrated to be a modulating and amplifying agent in the onset and progression of ARVD/C in general is discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom